The market has been high on Citius Pharmaceuticals Inc (CTXR) stock recently. CTXR gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CTXR Stock Today?
Citius Pharmaceuticals Inc (CTXR) stock is higher by 7.66% while the S&P 500 is lower by -0.46% as of 3:12 PM on Monday, Oct 19. CTXR has risen $0.09 from the previous closing price of $1.11 on volume of 2,297,114 shares. Over the past year the S&P 500 is higher by 15.34% while CTXR has risen 106.90%. CTXR lost -$0.55 per share in the over the last 12 months.
To screen for more stocks like Citius Pharmaceuticals Inc click here.
More About Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.
Click Here to get the full Stock Score Report on Citius Pharmaceuticals Inc (CTXR) Stock.
